Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
|Videos|November 15, 2017
Dr. Markman on Endpoints in Clinical Trials for Ovarian Cancer
Author(s)Maurie Markman, MD
Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses endpoints in clinical trials for ovarian cancer.
Advertisement
Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses endpoints in clinical trials for ovarian cancer.
Using overall survival (OS) as a primary endpoint for phase III randomized trials is no longer rational, says Markman. This endpoint assumes that what happens to a patient after they go on the trial is going to be similar for patients on either arm of the study.
Therefore, holding a drug or combination “hostage” to an OS endpoint is irrational and risky, explains Markman.
Advertisement
Related to this article
With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
4
Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia
5